Glioblastoma Multiforme Treatment Market Is Likely to Grasp the CAGR of 8.1 percent by 2029, Size, Share, Challenges - openPR
| TEV Stock | EUR 20.60 0.30 1.44% |
Roughly 62% of Teva Pharmaceutical's investor base is looking to short. The analysis of current outlook of investing in Teva Pharmaceutical Industries suggests that many traders are alarmed regarding Teva Pharmaceutical's prospects. The current market sentiment, together with Teva Pharmaceutical's historical and current headlines, can help investors time the market. In addition, many technical investors use Teva Pharmaceutical stock news signals to limit their universe of possible portfolio assets.
Teva Pharmaceutical stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Teva daily returns and investor perception about the current price of Teva Pharmaceutical Industries as well as its diversification or hedging effects on your existing portfolios.
Teva |
Glioblastoma Multiforme Treatment Market Is Likely to Grasp the CAGR of 8.1 percent by 2029, Size, Share, Challenges openPR
Read at news.google.com
 |
Teva Pharmaceutical Fundamental Analysis
We analyze Teva Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Teva Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Teva Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Teva Pharmaceutical is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Teva Pharmaceutical Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Teva Pharmaceutical stock to make a market-neutral strategy. Peer analysis of Teva Pharmaceutical could also be used in its relative valuation, which is a method of valuing Teva Pharmaceutical by comparing valuation metrics with similar companies.
Peers
Teva Pharmaceutical Related Equities
| MM3 | Merit Medical | 1.54 | ||||
| K41 | SCANDMEDICAL SOLDK-040 | 1.43 | ||||
| ARW | Arrow Electronics | 0.89 | ||||
| NUC | Nucletron Electronic | 0.00 | ||||
| 4WO | Peijia Medical | 2.27 |
Complementary Tools for Teva Stock analysis
When running Teva Pharmaceutical's price analysis, check to measure Teva Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharmaceutical is operating at the current time. Most of Teva Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Teva Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharmaceutical's price. Additionally, you may evaluate how the addition of Teva Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |